Ayurvedic 'Rasayana' therapy shows promise in advanced pancreatic cancer, Pune study presented at global meet
VMPL
Pune (Maharashtra) [India], May 4: In what could open a new line of model of care for one of the deadliest cancers, a Pune-based study on an Ayurvedic 'Rasayana' therapy has indicated improved survival and quality of life in patients with advanced pancreatic cancer. The findings were presented at the annual meeting of the American Association for Cancer Research held in San Diego, USA, drawing attention from the global oncology community.
Pancreatic cancer is widely regarded as one of the most challenging malignancies to treat, often diagnosed at a late stage when therapeutic options are limited. In such cases, average survival typically ranges between three to six months. However, the Pune study observed that patients receiving the Ayurvedic Rasayana Therapy (ART) showed a median survival of 10 to 11 months.
Dr Bendale said the therapy works by enhancing the body's intrinsic strength and resilience to fight cancer. "In advanced pancreatic cancer, where treatment options are often exhausted, Rasayana therapy offers patients a chance to live longer with dignity and improved well-being," he noted.
With global platforms like AACR recognising such work, the Pune study is expected to contribute to a broader re-evaluation of traditional medicine systems in cancer care, particularly for patients with limited treatment options.
(ADVERTORIAL DISCLAIMER: The above press release has been provided by VMPL. ANI will not be responsible in any way for the content of the same.)
Next Story